Search for:
Facebook
Twitter
LinkedIn
YouTube
Contact Us
Careers
Buy QuickStrip
Careers
Buy QuickStrip
Home
About RDT
About RDT
Rapid Dose Therapeutics, RDT, is a Canadian bio-technology company which provides disruptive proprietary drug delivery technologies designed to improve patient outcomes.
Our Mission
Create enhanced rapid delivery therapeutics to improve healthcare outcomes for patients.
Board of Directors
Mark Upsdell
CEO
Peter Thilo Hasler
Director
Team Members
Mark Upsdell
CEO
Doug Hyland
Manager, Systems & Processes
Technology
RDT Technology
How rapid is a Rapid Dose Therapeutic? Studies show the QuickStrip™ delivery mimics blood concentrations over time to intravenous injection.
QuickStrip™
QuickStrip™ an orally administrable composition comprising a film forming agent that is used to effectively deliver a micronized therapeutic to allow the ready absorption of pharmaceuticals to patients.
RDT Benefits + Advantages
Use of QuickStrip™ delivery mimics an injection path with uptake speed comparable to intravenous administration.
Products
Over the Counter (OTC)
Rapid Energy
Vitamins
Vitamin B12
Melatonin
Where to Buy QuickStrip
Pharma Applications
QuickStrip™
Rapid Delivery
Elderly
Pediatrics
Neuro
Ease of Use
Dental Products
Quickstrip Dental Products
Dental Surveys & Partnership Opportunities
Medical CPD
Medical Cannibinoids
Overview + Uses
Collaborations
Partner Opportunities
Why choose RDT
Rapid Dose Therapeutics Inc. offers partners a significant advantage by helping them bring products to market using patented and protected technology.
Contact us
To learn more about our product, collaborate or how you could partner with RDT.
Investors
Investor Centre
Press Releases
Click to view our press releases
Regulatory Filings
Governance
Videos
Press Releases
News Archive
Select Page
Sign up to get full access to all our latest Press Releases
Sign Up
Press Releases
Press Release
RDT MD&A February 28 2023
June 29, 2023
RDT MD&A February 28 2023
Back to press releases page
2024
2023
2022
2021
2020
2019
2018
RDT MD&A February 28 2023
×
